Andrew Orth - Feb 28, 2022 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Chief Commercial Officer
Signature
/s/ Andrew Orth
Stock symbol
KRYS
Transactions as of
Feb 28, 2022
Transactions value $
$0
Form type
4
Date filed
3/1/2022, 08:22 PM
Previous filing
Jun 2, 2021
Next filing
Feb 28, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KRYS Common Stock 100 Feb 28, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Award $0 +50K $0.00 50K Feb 28, 2022 Common Stock 50K $63.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in four equal annual installments beginning on February 28, 2023.